XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1Close
Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]        
Revenue [1] $ 823,800 $ 457,058 $ 2,383,957 $ 813,737
Cost of revenue (exclusive of amortization shown separately below) [1] (645,311) (424,009) (1,773,889) (536,644)
Gross profit [1] 178,489 33,049 610,068 277,093 Close
Other income:        
Government support income [1] 83,842 117,680 346,917 698,625
Operating expenses:        
Selling, general and administrative expenses [1] (2,425,830) (1,898,754) (6,587,934) (5,594,461)
Development and regulatory approval expenses [1] (471,313) (299,898) (923,712) (380,363)
Depreciation and amortization [1] (318,923) (398,986) (916,796) (797,142)
Goodwill impairment [1] (4,096,490) (4,096,490)
Total operating expenses [1] (3,216,066) (6,694,128) (8,428,442) (10,868,456) Close
Loss from operations [1] (2,953,735) (6,543,399) (7,471,457) (9,892,738) Close
Other income (expense), net:         Close
Interest expense [1] (42,674) (86,125) (112,590) (163,957) Close
Realized foreign exchange income/(loss) [1] (996) 7,212 (1,551) (8,936) Close
Fair value gain on revaluation of financial instrument [1] 269,787 175,738 2,062,878 Close
Interest income [1] 10,640 508 14,288 9,587 Close
Total other income (expense), net [1] (33,030) 191,382 75,885 1,899,572 CloseClose
Total Other Income Expenses -66060.0 0.0 382764.0 0.0 151770.0 Close
Net loss [1] (2,986,765) [2] (6,352,017) [3] (7,395,572) (7,993,166) CloseClose
Net loss attributable to non-controlling interest [1] (9,098) (8,111) (23,060) (20,367)
Net loss attributable to Intelligent Bio Solutions Inc. [1] (2,977,667) (6,343,906) (7,372,512) (7,972,799)
Other comprehensive income/(loss), net of tax:        
Foreign currency translation gain/ (loss) [1] (144,026) [2] (77,787) [3] (86,909) 148,251
Total other comprehensive income/(loss) [1] (144,026) (77,787) (86,909) 148,251
Comprehensive loss [1] (3,130,791) (6,429,804) (7,482,481) (7,844,915)
Comprehensive loss attributable to non-controlling interest [1] (9,098) (8,111) (23,060) (20,367)
Comprehensive loss attributable to Intelligent Bio Solutions Inc. [1] $ (3,121,693) $ (6,421,693) $ (7,459,421) $ (7,824,548)
Net income per common unit, basic [1] $ (1.43) $ (68.67) $ (6.64) $ (104.04)
Net income per common unit, diluted [1] $ (1.43) $ (68.67) $ (6.64) $ (104.04)
Weighted average shares outstanding, basic [1] 2,079,864 92,389 1,110,089 76,629
Weighted average shares outstanding, diluted [1] 2,079,864 92,389 1,110,089 76,629
[1] Common stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse stock split effected on January 26, 2024, and a 1-for-20 reverse stock split effected on February 9, 2023, throughout the condensed consolidated financial statement unless otherwise stated.
[2] Common stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse stock split effected on January 26, 2024, and a 1-for-20 reverse stock split effected on February 9, 2023, throughout the condensed consolidated financial statement unless otherwise stated.
[3] Common stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse stock split effected on January 26, 2024, and a 1-for-20 reverse stock split effected on February 9, 2023, throughout the condensed consolidated financial statement unless otherwise stated.